Zymergen EBIT

Zymergen posts a EBIT of $-340M as of June 2022. That compares with $-300M in the prior-year period — down 14.4% year over year. That is below the Materials sector average of $15B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Zymergen's EBIT was $-300M. The latest reading is $-340M — a 14.4% year-over-year decrease (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

For Materials stocks, a EBIT near $15B is typical. Zymergen's $-340M is lower that level. That is roughly 102.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Zymergen's financial statement story. At $-340M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ZY's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $15B), and (3) consistency with growth and profitability. This page covers the first two; Zymergen's other metric pages and overview cover the third.